1.0M
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Alan A. Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 285,000 | 285,000 | - | - | Stock Option (right to buy) | |
| Alex C. Sapir | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 582,000 | 582,000 | - | - | Stock option - Right to Buy | |
| Curtis G. Oltmans | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 76,120 | 76,120 | - | - | Stock Option (right to buy) | |
| Alex C. Sapir | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 150,000 | 2,280,400 | - | - | Stock option - Right to Buy | |
| Alex C. Sapir | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 03 Jul 2024 | 150,000 | 193,360 (0%) | 0% | 3.3 | 490,500 | Common Stock |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Kathryn Haviland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Colin Hill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Sonja Banks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 07 May 2024 | 236 | 11,571 (0%) | 0% | 7.8 | 1,831 | Common Stock |
| Patrick Taylor Horn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 11.72 per share. | 08 Mar 2024 | 4,884 | 11,807 (0%) | 0% | 11.7 | 57,219 | Common Stock |
| Alex C. Sapir | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 11.35 per share. | 04 Mar 2024 | 43,360 | 43,360 (0%) | 0% | 11.3 | 492,028 | Common Stock |
| Oltmans Curtis G. | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 83,820 | 83,820 | - | - | Stock Option (right to buy) | |
| Tourangeau Gregory | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| A. Alan Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Alan Musso A. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 61,822 | 61,822 | - | - | Stock Option (right to buy) | |
| Alan A. Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 432,800 | 432,800 | - | - | Stock Option (right to buy) | |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director, Interim President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Sonja Banks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.31 per share. | 10 May 2023 | 210 | 15,992 (0%) | 0% | 3.3 | 695 | Common Stock |
| Curtis G. Oltmans | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Esther Rajavelu | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 16,100 | 16,100 | - | - | Stock Option (right to buy) | |
| Melvin H. Hayes | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director, Interim President & CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 13 Jan 2023 | 6,766 | 499,864 (2%) | 0% | 15 | 101,490 | Common Stock |
| Curtis G. Oltmans | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Melvin H. Hayes | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 137,000 | 137,000 | - | - | Stock Option (right to buy) | |
| Gregory Tourangeau | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 16,540 | 16,540 | - | - | Stock Option (right to buy) | |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Other type of transaction at price $ 0.00 per share. | 27 Jun 2022 | 500 | 14,500 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Sonja Banks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 8.09 per share. | 07 Jun 2022 | 71,435 | 506,630 (2%) | 0% | 8.1 | 577,895 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 71,435 | 86,523 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 07 Jun 2022 | 71,435 | 578,065 (2%) | 0% | 7.8 | 560,050 | Common Stock |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 02 Jun 2022 | 16,689 | 506,630 (2%) | 0% | 7.9 | 132,162 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 24,382 | 157,958 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 25,551 | 182,340 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 16,689 | 207,891 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 02 Jun 2022 | 24,382 | 506,630 (2%) | 0% | 8.1 | 197,592 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 24,382 | 531,012 (2%) | 0% | 7.8 | 191,155 | Common Stock |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 7.95 per share. | 02 Jun 2022 | 25,551 | 506,630 (2%) | 0% | 7.9 | 203,056 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 25,551 | 532,181 (2%) | 0% | 7.8 | 200,320 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 02 Jun 2022 | 16,689 | 523,319 (2%) | 0% | 7.8 | 130,842 | Common Stock |
| Gregory Tourangeau | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 3,250 | 16,202 (0%) | 0% | 0 | Common Stock | |
| Gregory Tourangeau | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 07 Apr 2022 | 5,631 | 512,261 (2%) | 0% | 7.8 | 44,147 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2022 | 5,631 | 224,580 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.01 per share. | 07 Apr 2022 | 5,631 | 506,630 (2%) | 0% | 24.0 | 135,228 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 34,464 | 289,998 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.26 per share. | 01 Apr 2022 | 52,552 | 506,630 (2%) | 0% | 24.3 | 1,274,775 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 52,552 | 559,182 (2%) | 0% | 7.8 | 412,008 | Common Stock |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.02 per share. | 01 Apr 2022 | 7,235 | 506,630 (2%) | 0% | 24.0 | 173,749 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 7,235 | 513,865 (2%) | 0% | 7.8 | 56,722 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 01 Apr 2022 | 34,464 | 541,094 (2%) | 0% | 7.8 | 270,198 | Common Stock |
| Robert J. Gould | Director | Sale of securities on an exchange or to another person at price $ 24.03 per share. | 01 Apr 2022 | 34,464 | 506,630 (2%) | 0% | 24.0 | 828,160 | Common Stock |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 52,552 | 230,211 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 7,235 | 282,763 | - | - | Stock Option (right to buy) | |
| Curtis G. Oltmans | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 340,000 | 340,000 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Judith A. Dunn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 140,890 | 140,890 | - | - | Stock Option (right to buy) | |
| Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 59,744 | 59,744 | - | - | Stock Option (right to buy) | |
| Esther Rajavelu | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Sonja Banks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 10 Nov 2021 | 1,000,000 | 3,962,202 (16%) | 4% | - | Common Stock | |
| Mark J. Levin | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 22 Sep 2021 | 1,000,000 | 4,962,202 (21%) | 4% | - | Common Stock | |
| Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 32,000 | 32,000 (0%) | 0% | 7.8 | 250,880 | Common Stock |
| Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 28,000 | 243,571 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 32,000 | 271,571 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 23.75 per share. | 10 Aug 2021 | 28,000 | 0 (0%) | 0% | 23.8 | 665,000 | Common Stock |
| Bryan Stuart | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 28,000 | 28,000 (0%) | 0% | 7.8 | 219,520 | Common Stock |
| Bryan Stuart | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 10 Aug 2021 | 32,000 | 0 (0%) | 0% | 17.5 | 560,000 | Common Stock |
| Christopher Moxham | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 20,714 | 20,714 (0%) | 0% | 7.8 | 162,398 | Common Stock |
| Christopher Moxham | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 31,071 | 72,501 | - | - | Stock Option (right to buy) | |
| Christopher Moxham | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 20,714 | 103,572 | - | - | Stock Option (right to buy) | |
| Christopher Moxham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 10 Aug 2021 | 31,071 | 0 (0%) | 0% | 18 | 559,278 | Common Stockm |
| Christopher Moxham | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 10 Aug 2021 | 31,071 | 31,071 (0%) | 0% | 7.8 | 243,597 | Common Stock |
| Christopher Moxham | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 10 Aug 2021 | 20,714 | 0 (0%) | 0% | 17 | 352,138 | Common Stock |
| James A. Geraghty | Director | Purchase of securities on an exchange or from another person at price $ 9.16 per share. | 28 Jun 2021 | 10,000 | 90,714 (0%) | 0% | 9.2 | 91,600 | Common Stock |
| Curtis G. Oltmans | SVP, General Counsel | Purchase of securities on an exchange or from another person at price $ 9.01 per share. | 28 Jun 2021 | 1,088 | 1,088 (0%) | 0% | 9.0 | 9,803 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Purchase of securities on an exchange or from another person at price $ 9.00 per share. | 28 Jun 2021 | 2,300 | 2,300 (0%) | 0% | 9 | 20,700 | Common Stock |
| Christopher Morabito | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 9.16 per share. | 28 Jun 2021 | 1,100 | 1,100 (0%) | 0% | 9.2 | 10,076 | Common Stock |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Mark J. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 163,000 | 163,000 | - | - | Stock Option (right to buy) | |
| Judith A. Dunn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 215,000 | 215,000 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.43 per share. | 15 Mar 2021 | 789 | 506,630 (2%) | 0% | 12.4 | 9,806 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.13 per share. | 15 Mar 2021 | 9,211 | 507,419 (2%) | 0% | 12.1 | 111,773 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 14.72 per share. | 22 Feb 2021 | 5,000 | 15,212 (0%) | 0% | 14.7 | 73,582 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 5,000 | 50,471 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 22 Feb 2021 | 5,000 | 20,212 (0%) | 0% | 7.8 | 39,200 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 14.56 per share. | 16 Feb 2021 | 1,673 | 516,630 (2%) | 0% | 14.6 | 24,367 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 14.19 per share. | 16 Feb 2021 | 6,542 | 518,303 (2%) | 0% | 14.2 | 92,830 | Common Stock |
| Christopher Moxham | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 269,390 | 269,390 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 134,376 | 134,376 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 21 Jan 2021 | 6,607 | 15,212 (0%) | 0% | 14 | 92,498 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.08 per share. | 20 Jan 2021 | 10,000 | 524,845 (2%) | 0% | 12.1 | 120,826 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 6,350 | 75,592 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 14 Sep 2020 | 6,350 | 133,438 (0%) | 0% | 7.8 | 49,784 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 08 Jul 2020 | 2,500 | 534,845 (2%) | 0% | 20 | 50,000 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2020 | 2,951 | 81,942 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 08 Jul 2020 | 2,951 | 127,088 (0%) | 0% | 20 | 59,020 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 08 Jul 2020 | 2,951 | 130,039 (0%) | 0% | 7.8 | 23,136 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 01 Jul 2020 | 1,071 | 65,714 (0%) | 0% | 18.3 | 19,599 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 30 Jun 2020 | 141 | 127,229 (0%) | 0% | 7.8 | 1,105 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 141 | 84,893 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Jun 2020 | 141 | 127,088 (0%) | 0% | 20 | 2,820 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.80 per share. | 25 Jun 2020 | 2,500 | 537,345 (2%) | 0% | 20.8 | 51,992 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 25 Jun 2020 | 1,459 | 68,244 (0%) | 0% | 4.8 | 7,047 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2020 | 1,459 | 12,277 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 25 Jun 2020 | 1,459 | 66,785 (0%) | 0% | 22 | 32,098 | Common Stock |
| James A. Geraghty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 9,285 | 9,285 | - | - | Stock Option (right to buy) | |
| Mark J. Levin | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 9,285 | 9,285 | - | - | Stock Option (right to buy) | |
| James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 9,285 | 9,285 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 9,285 | 9,285 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 10 Jun 2020 | 401 | 66,785 (0%) | 0% | 22 | 8,822 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2020 | 401 | 13,736 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 10 Jun 2020 | 401 | 67,186 (0%) | 0% | 4.8 | 1,937 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 09 Jun 2020 | 156 | 539,845 (2%) | 0% | 20 | 3,120 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.17 per share. | 05 Jun 2020 | 3,433 | 540,001 (2%) | 0% | 20.2 | 69,251 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 226 | 14,588 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.18 per share. | 04 Jun 2020 | 451 | 66,785 (0%) | 0% | 20.2 | 9,101 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2020 | 451 | 14,137 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.05 per share. | 04 Jun 2020 | 226 | 66,785 (0%) | 0% | 20.0 | 4,531 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 04 Jun 2020 | 226 | 67,011 (0%) | 0% | 4.8 | 1,092 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 04 Jun 2020 | 451 | 67,236 (0%) | 0% | 4.8 | 2,178 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 03 Jun 2020 | 1,500 | 544,734 (2%) | 0% | 20.1 | 30,192 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 03 Jun 2020 | 1,300 | 543,434 (2%) | 0% | 20.0 | 26,058 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 02 Jun 2020 | 45 | 66,785 (0%) | 0% | 20 | 900 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.82 per share. | 02 Jun 2020 | 45 | 66,830 (0%) | 0% | 4.8 | 217 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2020 | 338 | 14,814 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2020 | 45 | 15,152 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.18 per share. | 02 Jun 2020 | 338 | 66,785 (0%) | 0% | 20.2 | 6,820 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 02 Jun 2020 | 338 | 67,123 (0%) | 0% | 4.8 | 1,633 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 01 Jun 2020 | 2,797 | 546,234 (2%) | 0% | 20 | 55,940 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 01 Jun 2020 | 5 | 549,031 (2%) | 0% | 20 | 100 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 28 May 2020 | 1,919 | 550,426 (2%) | 0% | 20.0 | 38,391 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.08 per share. | 28 May 2020 | 1,390 | 549,036 (2%) | 0% | 20.1 | 27,911 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 28 May 2020 | 2,232 | 129,320 (0%) | 0% | 7.8 | 17,499 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 28 May 2020 | 2,232 | 127,088 (0%) | 0% | 20 | 44,640 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 2,232 | 85,034 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 200 | 15,197 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 600 | 15,397 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 28 May 2020 | 200 | 66,785 (0%) | 0% | 20.0 | 4,007 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 28 May 2020 | 200 | 66,985 (0%) | 0% | 4.8 | 966 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 28 May 2020 | 600 | 66,785 (0%) | 0% | 20 | 12,000 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 28 May 2020 | 600 | 67,385 (0%) | 0% | 4.8 | 2,898 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 27 May 2020 | 448 | 127,536 (0%) | 0% | 7.8 | 3,512 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2020 | 448 | 87,266 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 27 May 2020 | 448 | 127,088 (0%) | 0% | 20 | 8,960 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 26 May 2020 | 2,500 | 552,345 (2%) | 0% | 20 | 50,000 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 26 May 2020 | 412 | 127,088 (0%) | 0% | 20 | 8,240 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2020 | 412 | 87,714 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 26 May 2020 | 412 | 127,500 (0%) | 0% | 7.8 | 3,230 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.83 per share. | 12 May 2020 | 1,860 | 68,645 (0%) | 0% | 4.8 | 8,984 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2020 | 1,860 | 15,997 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 12 May 2020 | 1,860 | 66,785 (0%) | 0% | 18 | 33,480 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 11 May 2020 | 7,500 | 21,071 (0%) | 0% | 16 | 120,000 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 02 Mar 2020 | 315 | 66,785 (0%) | 0% | 18.1 | 5,710 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 17.26 per share. | 02 Mar 2020 | 1,828 | 67,100 (0%) | 0% | 17.3 | 31,545 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 18.61 per share. | 24 Feb 2020 | 250 | 28,571 (0%) | 0% | 18.6 | 4,653 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 17.43 per share. | 24 Feb 2020 | 2,102 | 28,821 (0%) | 0% | 17.4 | 36,643 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 24 Feb 2020 | 2,648 | 30,923 (0%) | 0% | 16.2 | 42,857 | Common Stock |
| Robert J. Gould | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 19 Feb 2020 | 2,500 | 554,845 (2%) | 0% | 20 | 50,000 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2020 | 6,088 | 88,126 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 19 Feb 2020 | 6,088 | 127,088 (0%) | 0% | 20 | 121,760 | Common Stock |
| Owen Wallace | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 19 Feb 2020 | 6,088 | 133,176 (0%) | 0% | 7.8 | 47,730 | Common Stock |
| Diego Cadavid | SVP Clinical Development | Sale of securities on an exchange or to another person at price $ 17.33 per share. | 03 Feb 2020 | 2,143 | 68,928 (0%) | 0% | 17.3 | 37,142 | Common Stock |
| Robert J. Gould | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 58,900 | 58,900 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 55,440 | 55,440 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 33,100 | 33,100 | - | - | Stock Option (right to buy) | |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 23 Jan 2020 | 262 | 33,571 (0%) | 0% | 18.1 | 4,730 | Common Stock |
| Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 17.17 per share. | 23 Jan 2020 | 4,738 | 33,833 (0%) | 0% | 17.2 | 81,372 | Common Stock |
| Katina Dorton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 18,571 | 18,571 | - | - | Stock Option (right to buy) | |
| Mark J. Levin | Director, Ten Percent Owner | 22 Jul 2019 | 5,595,238 | 5,880,952 (25%) | 23% | 0 | Common Stock | ||
| Mark J. Levin | Director, Ten Percent Owner | 22 Jul 2019 | 39,166,667 | 0 | - | - | Series A Preferred Stock | ||
| Mark J. Levin | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 22 Jul 2019 | 81,250 | 5,962,202 (25%) | 0% | 16 | 1,300,000 | Common Stock |
| James A. Geraghty | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 9,285 | 9,285 | - | - | Stock Option (right to buy) | |
| Robert J. Gould | Director, See Remarks, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 107,142 | 107,142 | - | - | Stock Option (right to buy) | |
| Bryan Stuart | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 28,571 | 28,571 | - | - | Stock Option (right to buy) | |
| Owen Wallace | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 44,493 | 44,493 | - | - | Stock Option (right to buy) | |
| Diego Cadavid | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 12,784 | 12,784 | - | - | Stock Option (right to buy) | |
| James J. Collins | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 5,714 | 5,714 | - | - | Stock Option (right to buy) | |
| Alan Ezekowitz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 5,714 | 5,714 | - | - | Stock Option (right to buy) | |
| Peter Thomson | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2019 | 7,078 | 7,078 | - | - | Stock Option (right to buy) |